Semaglutide Patent Expiry in India: GLP-1 Drugs, Benefits, Risks & Social Impact

The expiry of the semaglutide patent in India on March 20 has triggered a wave of aggressive GLP-1 launches in the country.

Scientific and Commercial Context

• About Semaglutide: A GLP-1 receptor agonist drug used to treat type-2 diabetes and obesity, which mimics the GLP-1 hormone to signal satiety to the brain, thereby reducing appetite and regulating blood sugar levels.
  • GLP-1 hormone (Glucagon-Like Peptide-1): A hormone released from the gut after meals that stimulates insulin secretion, slows gastric emptying, and signals satiety to the brain.
• Brand Differentiation: The same molecule is marketed as Ozempic (for diabetes management) and Wegovy (for weight loss).
• Patent Expiry: With the 20-year patent protection expiring, generic production becomes possible, reducing costs and increasing accessibility of weight-loss drugs.
• Societal Impact: The shift of GLP-1 drugs, such as Ozempic and Wegovy, from expensive, patented medicines to affordable generics is expected to have significant societal and public health implications.

From Medical Treatment to Cosmetic Consumption

• Rising Lifestyle Diseases: India faces growing obesity and cardiovascular risks (highlighted in NFHS-5), where such drugs could play a therapeutic role.
• Shift to Aesthetic Use: There is concern that usage may move from clinical treatment to cosmetic weight loss, driven by beauty standards rather than health needs.
• End of Thinness as Elite Privilege: Earlier, maintaining a thin body often required expensive fitness regimes and lifestyle choices.
  • However, cheap medication could replace discipline with pharmaceutical intervention.

Changing Social Norms and Pressures

• Ease Creating Expectation: When weight loss becomes medically easy and affordable, choosing not to lose weight may be socially questioned.
• Intensified Body Shaming: Obesity may increasingly be perceived as a personal failure rather than a natural variation in body type.
• Body as Social Capital: In India, appearance already influences marriage markets, hospitality jobs, and social mobility, potentially making thinness an implicit social requirement.

Theoretical Perspectives

• Biopolitics (Michel Foucault): Society and institutions may indirectly regulate bodies through norms, creating social pressure to medically modify one’s body.
• The Beauty Myth (Naomi Wolf): Expectations of thinness, especially for women, may function as a mechanism of social control disguised as personal choice.

Enroll now for UPSC Online Course

Impact on Fashion and Cultural Diversity

• Risk to Body Diversity: The growing acceptance of plus-size representation in fashion may weaken.
• Standardisation of Bodies: If pharmaceutical weight loss becomes widespread, fashion markets may shift towards narrower body-size ranges, reducing inclusivity.

Ethical and Policy Dilemmas

• Public Health Benefit: GLP-1 drugs can significantly reduce the risks of diabetes, obesity, and cardiovascular disease, offering major health gains.
  • However, mass consumption raises concerns about the medicalisation of normal bodies, pharmaceutical marketing, and social coercion.
• Autonomy vs. Social Pressure: The key ethical challenge is balancing individual freedom of choice with growing societal expectations to conform to norms of thinness.

Check Out UPSC CSE Books

Visit PW Store

Conclusion

While affordable GLP-1 drugs can revolutionise the fight against non-communicable diseases, their widespread use may also reshape social norms around body image, raising critical questions about health, autonomy, and the medicalisation of beauty.